Development of clinical guidelines for the pharmacological management of behavioural disturbance and aggression in people with psychosis

Australasian Psychiatry

Volumn 13, Issue 3, 2005, Pages 247-252

  Castle, David ^a,b   Daniel, Jeffrey ^b   Knott, Jonathan ^b   Fielding, John ^b   Goh, Joyce ^c   Singh, Bruce ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c NorthWestern Mental Health   (Australia)

Author keywords

Antipsychotics; Behavioural disturbance; Benzodiazepines; Clinical practice guidelines; Psychosis

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CLONAZEPAM; DROPERIDOL; HALOPERIDOL; LORAZEPAM; MIDAZOLAM; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE; ZUCLOPENTHIXOL ACETATE;

AGGRESSION; BEHAVIOR DISORDER; BIPOLAR DISORDER; CARDIOTOXICITY; CONSENSUS DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MENTAL HEALTH CARE PERSONNEL; MENTAL HEALTH SERVICE; MENTAL HOSPITAL; PRACTICE GUIDELINE; PROGNOSIS; PSYCHOSIS; RESPIRATION DEPRESSION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

ACUTE DISEASE; AGGRESSION; DRUG THERAPY; FOCUS GROUPS; HUMANS; MONITORING, PHYSIOLOGIC; PRACTICE GUIDELINES; PSYCHOTIC DISORDERS; SAFETY; TREATMENT OUTCOME;

EID: 29144506088     PISSN: 10398562     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1665.2005.02194.x     Document Type: Review

References (16)

1. Castle DJ, Alderton D. Management of acute arousal in psychosis. In: Castle DJ, Copolov DL, Wykes T, eds. Pharmacological and Psychosocial Treatments in Schizophrenia. London: Martin Dunitz, 2003; 89-102.
2. McAllister-Williams R, Ferrier IN. Rapid tranquillisation: time for a reappraisal of options for parenteral therapy. British Journal of Psychiatry 2001; 179: 485-489.
3. Kao LW, Kirk MA, Evers SJ, Rosenfeld SH. Droperidol, QT prolongation, and sudden death: what is the evidence? Annals of Emergency Medicine 2003; 41: 546-558.
4. Hughes DH, Kleepsies PM. Treating aggression in the psychiatric emergency service. Journal of Clinical Psychiatry 2003; 64(Suppl. 4): 10-15.
5. Lambert T, Castle DJ. Pharmacological treatments for schizophrenia. Medical Journal of Australia (Suppl) 2003; 178: S57-S61.
6. McPherson R, Anstee B, Dix R. Guidelines for the management of acutely disturbed patients. Advances in Psychiatric Treatment 1996; 2: 194-201.
7. Geffen J, Sorensen L, Stokes J, Cameron A, Roberts MS, Geffen L. Pro re nata medication for psychoses: an audit of practice in two metropolitan hospitals. Australian and New Zealand Journal of Psychiatry 2002; 36: 649-656.
8. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP, Ross RW. Treatment of behavioural emergencies. Postgraduate Medicine Special Report 2001; May: 1-88.
9. Garza-Trevino ES, Hollister LE, Overall JE, Alexander WF. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry 1989; 146: 1598-1601.
10. Currier GW, Chou JC-Y, Feifel D et al. Acute treatment of psychotic agitation: a randomised comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. Journal of Clinical Psychiatry 2004; 65: 386-394.
11. Brook S, Walden J, Mertens C, Benattia I, Siu C. Sequential im/oral ziprazidone versus haloperidol in schizophrenia with anxiety. Schizophrenia Research 2003; 60 (Suppl.): 275.
12. Wright P, Birkett M, David SR et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. American Journal of Psychiatry 2001; 158: 1149-1151.
13. Breier A, Meehan K, Birkett M et al. A double-blind, placebo-controlled comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry 2002; 59: 441-448.
14. Kay SR, Opler LA, Lindenmeyer JP. Reliability and validity of the Positive and Negative Symptom Scale (PANSS) for schizophrenics. Psychiatry Research 1988; 23: 99-110.
15. Guy W. ECDEU Assessment Manual for Psychopharmacology. Bethesda, MD: US Department of Health, Education, and Welfare, 1976.
16. Barnes CW, Alderton D, Castle D. The development of clinical guidelines for the use of Zuclopenthixol acetate. Australasian Psychiatry 2002; 10: 54-58.